|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM036960098 |
| 003 |
DE-627 |
| 005 |
20231221140020.0 |
| 007 |
tu |
| 008 |
231221s1986 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0124.xml
|
| 035 |
|
|
|a (DE-627)NLM036960098
|
| 035 |
|
|
|a (NLM)3714755
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yasky, J
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients
|
| 264 |
|
1 |
|c 1986
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.07.1986
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Twenty-three optimally digitalized patients with congestive heart failure completed a 4-week treatment period with a fixed-drug association of 20 mg furosemide plus 50 mg spironolactone. Eleven patients responded with a 75% decrease in cardiac failure score on a daily dose of 1 capsule of the combination. The remaining 12 patients were initiated on the same dose, but needed, at the end of the first 14 days, an additional capsule (making a daily total of 40 mg furosemide and 100 mg spironolactone) over the next 2 weeks. On this dose, the patients achieved an average reduction of 52% in their cardiac failure score. There were no treatment failures. Electrolyte abnormalities and side-effects were not observed. The combination product, in a daily dose of 1 or 2 capsules, was found useful and well tolerated in the management of congestive heart failure
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Digitalis Glycosides
|2 NLM
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a lasilacton
|2 NLM
|
| 650 |
|
7 |
|a 124199-68-4
|2 NLM
|
| 650 |
|
7 |
|a Spironolactone
|2 NLM
|
| 650 |
|
7 |
|a 27O7W4T232
|2 NLM
|
| 650 |
|
7 |
|a Furosemide
|2 NLM
|
| 650 |
|
7 |
|a 7LXU5N7ZO5
|2 NLM
|
| 700 |
1 |
|
|a Ledesma, G A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tutera, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Collia, L F
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 4(1986), 8 vom: 03., Seite 473-9
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:4
|g year:1986
|g number:8
|g day:03
|g pages:473-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 4
|j 1986
|e 8
|b 03
|h 473-9
|